1.1Glutamate receptor modulation
An arylcyclohexylamine such as ketamine blocks the open ion channel of an NMDA receptor. A patch-clamp assay measures the reduction in current during repeated receptor activation.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An arylcyclohexylamine such as ketamine blocks the open ion channel of an NMDA receptor. A patch-clamp assay measures the reduction in current during repeated receptor activation.
A cytokine-neutralizing antibody binds a selected inflammatory cytokine, and a coenzyme Q10 preparation supplies an electron carrier used by the mitochondrial respiratory chain. A cytokine activity assay and a cellular oxygen-consumption assay provide a separate readout for each target.
A calcium-flux assay measures activation in cells expressing the serotonin 2A receptor. An immunoassay and a deacetylation assay check that sirtuin 1 abundance and activity stay within predefined baseline tolerances at the selected exposure.
Timed plasma samples and a pharmacokinetic model estimate apparent clearance for each active ingredient. The system calculates each amount from its clearance estimate and target exposure, then calculates the ratios from those amounts.
A single rapamycin active ingredient forms a complex with an intracellular binding protein and inhibits a kinase complex that regulates protein synthesis and autophagy. Phosphorylation of a downstream substrate and autophagic flux provide separate assay readouts for the two processes.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A laboratory platform distributes donor-derived neural spheroids across replicate wells and reserves matched wells for vehicle controls. Baseline assays rank cellular senescence, mitochondrial function, oxidative stress, and neuroplasticity against distributions from control cultures of the same age. A liquid handler combines psilocin with pathway modulators at ratios drawn from a predefined table indexed by the four ranks. Follow-up measurements from sister wells guide selection of the next mixture for each donor line.
Coenzyme Q10 replaces the nicotinamide adenine dinucleotide precursor in the mitochondrial component of the mixture and serves as an electron carrier in the mitochondrial respiratory chain. A ratio table maps the mitochondrial function score to a coenzyme Q10 amount relative to the tryptamine component. Separate entries in the same table set the amounts of modulators for cellular senescence, inflammation, and neuroplasticity. Follow-up measurements of mitochondrial respiration update the mitochondrial score used for the next formulation.
Flow cytometric fluorescence in situ hybridization replaces amplification-based telomere measurement in the biomarker panel. A fluorescent peptide nucleic acid probe binds telomeric repeats, and a flow cytometer measures the signal in gated lymphocyte and granulocyte populations alongside an internal reference cell population. The software converts the normalized signals to age-adjusted scores and uses their mean as the telomere maintenance score. This score joins the other pathway scores in the table that sets the modulator ratios relative to the tryptamine component.
The biomarker panel covers cellular senescence, mitochondrial function, inflammation, oxidative stress, epigenetic aging, and neuroplasticity. Two baseline collections occur seven days apart, and each marker score uses the mean of the two standardized measurements. The six pathway scores map to four preset ratio bands for the corresponding modulators relative to the tryptamine component. Follow-up collections every 28 days trigger a review when a pathway score differs from its predicted value by at least one reference standard deviation at two consecutive visits.
A pharmacy compounding system receives a reviewed formulation record with a target mass and tolerance for the tryptamine component and each of at least four pathway modulators. Barcode scans match each source container to its ingredient record, and a connected balance records the incremental mass during dispensing. The system holds the formulation for review when a measured mass falls outside its tolerance and records the actual ingredient ratios with the batch identifier. Follow-up biomarker records use that identifier to associate each observation with the measured composition.
A Bayesian state-space model estimates a latent severity score for each pathway from serial biomarkers, assay variability, and collection times. At each visit, the software compares the new measurements with the predictive intervals generated before those measurements entered the model. When a pathway falls outside its interval at two consecutive visits, the software updates the trajectory and ranks predefined modulator ratios by predicted deviation from target scores. The review screen displays the current and proposed ratios relative to the tryptamine component alongside the measurements that triggered the update.
Crystalline psilocybin serves as the tryptamine active ingredient in a dry granulate with a cellulose filler. A chromatographic assay measures psilocybin content and separately quantifies psilocin formed during storage.
A senolytic compound targets senescent-cell survival, coenzyme Q10 participates in mitochondrial electron transport, and a cyclooxygenase inhibitor reduces inflammatory prostaglandin synthesis. N-acetylcysteine supplies cysteine for glutathione synthesis to address oxidative stress.
Software converts each biomarker to a standardized deviation from a reference distribution and orients the score so that larger values indicate greater impairment. The system averages scores within each pathway and uses a bounded lookup table to assign each modulator an amount relative to a fixed tryptamine amount.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In one embodiment, the active ingredient is a crystalline form of psilocybin and psilocin, such as co-crystal Form A, co-crystal Form B or co-crystal Form C described herein.A · US 2025/0177422 A1 · ¶ 254
In one embodiment, the active ingredient is a crystalline form of psilocybin and psilocin, such as crystalline Form A, crystalline Form B or From C described herein.B · US 2025/0375420 A1 · ¶ 114
It was found that treatment with the psilocybin+psilocin in a 1:1 molar ratio combination resulted in an approximate 20% increase in neurogenesis from single dosing over six hours with a matching decrease in proliferation. Neuronal length two days after administration was observed to be greatest with the psilocybin+psilocin in a 1:1 molar ratio combination, approximately doubling at the highest dose and greater than psilocybin alone.B · US 2025/0375420 A1 · ¶ 237
An empty cell means only that no passage was reproduced there.
The psilocybin and psilocin co-crystal may further be used to induce neuroplasticity and increase brain-derived neurotrophic factor (BDNF) levels, all with a lowered risk of cardiac adverse events.A · US 2025/0177422 A1 · ¶ 2
However, there has been far less research on the potential clinical benefits of longer-term microdosing, although there are a large number of anecdotal reports and poorly controlled studies purporting to demonstrate a wide range of benefits.A · US 2025/0177422 A1 · ¶ 5
In contrast to psilocybin, psilocin is chemically unstable and rapidly oxidizes when exposed to air.B · US 2025/0375420 A1 · ¶ 4
One such treatment may be a crystalline form of psilocybin and psilocin, especially for use in disorders resistant to current treatments.B · US 2025/0375420 A1 · ¶ 7
patent.fyi, US 2026/0355156 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355156/, SHA-256 7848083a779c34eae0df1ce626a5c3da4281fc24763287eddd76e736185d928c